Skip to main content
Figure 7 | BMC Cancer

Figure 7

From: MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

Figure 7

The MP470-Erlotinib combination causes TGI in an LNCaP xenograft mouse model. (a). 2 × 107 LNCaP cells were injected into the flanks of SCID male mice and tumors grown for 4 weeks to achieve a volume of ~100 mm3. The mice were pair matched into different groups (12 mice/group). The mice were treated with DMSO, Erlotinib (80 mg/kg), MP470 (50 mg/kg), Erlotinib (80 mg/kg) plus MP470 (50 mg/kg) IP daily for 14 days (starting day 30 and ending day 44), and mean tumor volume ± SEM are graphed. * P-value = 0.008. (b). 2 × 107 LNCaP cells were injected into the flanks of SCID male mice and three groups (12 mice/group) were pair matched when the tumors grew to ~300 mm3. The mice were treated with DMSO (control), Erlotinib (80 mg/kg) plus MP470 (10 mg/kg or 20 mg/kg, respectively) by IP daily for 22 days (starting day 27 and ending day 49), and the mean tumor volume ± SEM are graphed. * P-value = 0.01.

Back to article page